Bullet-Proof Data Quality, Enhance RWE Generation with AI, & Consolidate Integrated Evidence Planning to Transform Your RWE Strategy
Welcome to the 13th IMPACCT Real-World Evidence Summit
As the CMS introduces new guidance for RWD studies, the FDA announces a RWE Center to promote its use in regulatory decision-making, and RWD becomes more accessible, investment is pouring into RWE generation. It is evident RWE will play an increasingly pivotal role in the drug development lifecycle, but questions still remain for the experts optimizing and applying RWE.
As the only industry meeting uniting RWE experts, the 13th IMPACCT Real-World Evidence Summit offers you the unique opportunity to consolidate, innovate and optimize your RWE strategy at all stages of the drug development lifecycle.
Connect with 140+ industry pioneers from Pfizer, AstraZeneca, Alexion, Moderna, and Boehringer Ingelheim, as they share first-hand case studies in fortifying data quality, validating use of AI and predictive modeling in data analysis, leveraging RWE to support regulatory submissions and more.
Access the Brand-New Agenda
140+ industry experts
29+ world-class speakers
3 days of content-led sessions
Latest industry case-studies and examples
Your Expert Speaker Faculty:
Vanja Sikirica
Executive Director - Epidemiology, Health Economics Outcomes Research & Patient Centered Outcomes
Moderna
Previously Attending Companies:
Proud to Partner With:
What Your Peers Thought:
“The interaction with RWE experts from other pharma companies and vendors was valuable. The content was extremely enriching”
Past Attendee, Senior Director, Real-World Evidence, Pfizer
“This meeting provided state-of-the art presentations addressing challenges those working in the health data space and evidence generation are facing”
Past Attendee, Director, Value & Access, Eli Lilly & Co
“Very professional and knowledgeable speakers across both RWE clinical research and value and access”
Past Attendee, Head of Strategy, Johnson & Johnson
